Thank you for Subscribing to Life Science Review Weekly Brief
Numerous immunotherapeutic approaches have entered the global market, highlighting significant clinical success by harnessing the potential of the immune system to selectively target cancer cells.
FREMONT, CA: Targeted therapies like immunotherapy harness the potential of the immune system to selectively target cancer cells. A wide range of immunotherapeutic approaches, including therapeutic antibodies, immune checkpoint inhibitors, vaccines, interferon, and others, have entered the global market and demonstrated significant clinical success. However, drug resistance is a primary limitation restraining its growth in the global market. As numerous immunotherapeutic approaches have shown success as monotherapy, research studies are focused on evaluating their potential in combination therapy to increase its therapeutic potential. Each immunotherapeutic combination has a unique mechanistic synergism offering an exacerbated and potentially rewarding feat in the field of Immuno oncology.
The progress in the area of bioinformatics has resulted in the identification of various next-generation immune checkpoint targets such as lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain containing -3 (TIM-3), T cell immunoglobulin and ITIM domain (TIGIT), V-domain Ig suppressor of T cell activation (VISTA), etc. All these next-generation immune checkpoint inhibitors have shown encouraging responses in combination with PD-1/PD-L1 or CTLA-4 inhibitors, which will have a positive impact on market growth.
The pipeline of LAG-3 inhibitors is highly crowded, with more than 50 clinical trials.
The significant drugs in clinical development include IMP701, FS118, TSR-033, and several others that are rapidly demonstrating positive responses in clinical trials. Many pharmaceutical companies have developed a robust pipeline of TIGIT inhibitors indicated for the management of several cancers. Current clinical trials are primarily evaluating the role of TIGIT inhibitors in combination with PD-1/PD-L1 inhibitors of CTLA-4 inhibitors. The extensive research activities have paved the way for the development of a robust clinical pipeline of TIGIT inhibitor drugs.
TIM3 is another immune checkpoint inhibitor which has gained interest from pharmaceutical companies and this pipeline is small. However, the rising interest from the government and investments from pharmaceutical companies will accelerate the number of clinical pipeline products. Recently, a company has developed advanced-stage TIM-3 inhibitors which are currently being evaluated in phase-II clinical trials. Recent data reveals that anti-TIM-3 antibody is well-tolerated as monotherapy and in combination with the PD-1 inhibitor.
The promising response of combination cancer immunotherapy in clinical studies and the market has surged pharmaceutical investments in this domain. Many key players in the market have adopted strategic alliances such as collaboration, partnerships, or joint ventures to propel the growth of the market. Reports indicate that the global combination cancer immunotherapy will massively grow which is majorly attributed to its encouraging response and superior efficacy in comparison to monotherapy. Furthermore, the novel approach aids in targeting the multifactorial nature of cancer.